Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
about
Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug developmentCardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityBariatric endocrinology: principles of medical practice.Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implicationsPharmacological treatment of obesity in children and adolescents: present and futureMetabolic syndrome and migraine.2014 clinical practice guidelines for overweight and obesity in Korea.Management of diabetes across the course of disease: minimizing obesity-associated complicationsPhentermine and topiramate for the management of obesity: a review.Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.Obesity in 2010: the future of obesity medicine: where do we go from here?Treatment of lipid disorders in obesity.Drug treatment of obesity in cardiovascular disease.Lorcaserin: a review of its use in chronic weight management.Fixed-dose combination of phentermine-topiramate for the treatment of obesity.New pharmacological treatments for the management of obesity.Tolerability and safety of the new anti-obesity medications.Combination phentermine and topiramate extended release in the management of obesity.Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.Insulin sensitivity deteriorates after short-term lifestyle intervention in the insulin sensitive phenotype of obesity.
P2860
Q22241480-34F43B84-3EDB-4956-920B-E4A2C0E49248Q33572190-53AB7724-4169-48BE-954C-D2AED12B8C87Q33677790-70731E14-FEED-4836-BC28-7E2BB9DA2FF1Q33717424-40A6B7FF-FED2-46C5-9F2A-E5DD9E0756B6Q34442880-3FE15D65-3760-41CA-8093-F4CFB07C32AFQ34645695-731170F8-5F7C-44C7-AAC4-52F76E050655Q34839544-2883ACF3-C8C5-4D8E-84DF-074D55E841B1Q35574560-E4CA45E4-6C02-47BE-ADC9-0139F87CCC35Q36758207-0A7CF8AC-BB66-4F6A-9720-221E2C147ECFQ37589010-75684A1E-E253-4585-9C6E-A1DAD5610371Q37832119-FEF9B96F-7669-47F3-A1F8-CFEE36F9A14BQ37923978-197295AF-7F60-44F5-9722-413200C8AADCQ37980171-79A592F7-8A54-4236-BAE9-E7845D1C3E44Q38093129-3CCD2F52-D73B-44D7-9AD6-9B78BE4AB46AQ38105146-1D726147-E082-4DA4-AF40-C16214C74D7FQ38211754-B29A231A-A659-4E56-A892-DF0BCD063F7FQ38237336-A529888F-FDBD-4B0A-BDC0-6F4D2A87CD63Q38469824-B1600354-60EE-42BF-9646-F5DAB553ABDEQ49547050-32735FEE-4B5E-4963-8FE7-87AB59D04B33Q53178732-02D5B937-AA51-46D3-B987-5514F141A639
P2860
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@en
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@nl
type
label
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@en
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@nl
prefLabel
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@en
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@nl
P2860
P356
P1476
Phentermine, topiramate and th ...... k fat') and metabolic disease.
@en
P2093
Harold Bays
P2860
P304
P356
10.1586/ERC.10.125
P577
2010-08-16T00:00:00Z